Last reviewed · How we verify
NCT03519529
Sex Hormone Binding Globulin, Testosterone and Glycemic Control in Patients With Type 2 Diabetes
trial in Type2 Diabetes in 250 participants. Completed in 20 April 2018.
15 April 2018
Quick facts
| Lead sponsor | Nanjing First Hospital, Nanjing Medical University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 1 January 2015 |
| Primary completion | 15 April 2018 |
| Estimated completion | 20 April 2018 |
Conditions studied
- Type2 Diabetes — all drugs for Type2 Diabetes →
Sponsor
Nanjing First Hospital, Nanjing Medical University
Who can join
Eligibility, male only, with Type2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sex hormone-binding globulin(SHBG) is a surrogate marker of insulin resistance. This study aims at the characteristic and clinical significance of SHBG and testosterone in patients with type 2 diabetes(T2D).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Association of high circulating testosterone with increased glycaemic variability in type 2 diabetes: A cross-sectional study in China.
Ding B, Sun R, Zhai XF, Lu TT, et al · · 2019 · cited 5× · PMID 30614187 · DOI 10.1002/dmrr.3126
Verify or expand the search:
- PubMed search for NCT03519529
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type2 Diabetes
Currently open trials in the same condition.
- NCT05277558 — Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D) · recruiting
- NCT05015283 — Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission · NA · recruiting
- NCT05006508 — Prevention With the Health and Lifestyle Tool · NA · active not recruiting
- NCT04717050 — Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity · NA · active not recruiting
- NCT05220917 — Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study · active not recruiting
Other Nanjing First Hospital, Nanjing Medical University trials
Trials by the same sponsor.
- NCT07349979 — PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy · NA · not yet recruiting
- NCT07505056 — Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas · Phase 3 · not yet recruiting
- NCT07397234 — Thyroid Cartilage Plane VS Superior Laryngeal Nerve Space Block in Awake Tracheal Intubation · NA · not yet recruiting
- NCT07455448 — Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study · completed
- NCT07385885 — Ultrasound-guided Non-invasive Simulation in Anesthesia Residency Training · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03519529 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanjing First Hospital, Nanjing Medical University
- Last refreshed: 11 May 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03519529.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing